Baidu
map

PCI术后胸痛,可能是哪些原因?

2016-05-16 charrychi 医学界

PCI是目前治疗冠心病的主要方法,具有明显的优越性。目前临床上有少数患者可出现术后胸痛的表现,其病因多种多样。一、缺血性胸痛(1)PCI术后血栓形成患者临床表现为持续性剧烈胸痛,伴大汗、恶心、呕吐等,心电图表现为ST段弓背抬高,心肌酶升高和肌钙蛋白阳性。需紧急复查冠脉造影明确,必要时PCI或其他治疗。(2)边支受累主要发生于分叉病变的介入治疗中,改善罪犯血管血运时,周边小血管受压或斑块移位进入边支

PCI是目前治疗冠心病的主要方法,具有明显的优越性。目前临床上有少数患者可出现术后胸痛的表现,其病因多种多样。

一、缺血性胸痛

(1)PCI术后血栓形成

患者临床表现为持续性剧烈胸痛,伴大汗、恶心、呕吐等,心电图表现为ST段弓背抬高,心肌酶升高和肌钙蛋白阳性。需紧急复查冠脉造影明确,必要时PCI或其他治疗。

(2)边支受累

主要发生于分叉病变的介入治疗中,改善罪犯血管血运时,周边小血管受压或斑块移位进入边支致其闭塞。心电图可表现ST段下移,化验肌钙蛋白高。细小分支病变给予扩冠、抗痉挛治疗即可,大的分支病变需要介入治疗。

(3)慢血流或无复流

常见于PCI时间较晚梗死面积大的患者,原因考虑:

①血栓导致的远端血管闭塞;
 ②血管再灌注损伤;
③介入操作导致血管痉挛; 
④内皮细胞损伤;
 ⑤炎性反应等。

心电图可表现为ST段下移,患者易于发生休克等,需密切观察。

(4)非完全血运重建

冠状动脉造影示多支多处血管病变,仅对主要的罪犯血管进行血运重建,对于其他病变给予药物治疗。可以考虑扩冠治疗。

二、非缺血性胸痛

(1) 焦虑、抑郁状态

患者多有焦虑等特点,胸痛部位不固定,呈游走性,心电图无明显异常,心肌酶及肌钙蛋白无异常。此类患者可考虑抗焦虑治疗。

(2)支架反应

发生于置入多枚支架、长支架等,血管外膜受牵张所致,患者可表现为胀痛,多在休息时出现,心电图无明显变化。术中需要选择恰当支架,并适当应用对吻技术等。


多为房颤,房速等快速心律失常,患者可表现为心前区不适、心悸、胀痛等。若病情允许可尽早应用β受体阻滞剂治疗。

除上述原因外,还包括呼吸系统病变、消化系统病变以及肋软骨炎等引起的胸痛,该类胸痛多无心电图、心肌酶改变,临床上需要仔细鉴别。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1633823, encodeId=2011163382348, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Thu Jan 12 04:11:00 CST 2017, time=2017-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486420, encodeId=f680148642040, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Wed May 18 02:11:00 CST 2016, time=2016-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86012, encodeId=c7978601254, content=每一个东西都是有寿命, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cache2.medsci.cn/upload/content/day_160326/201603262025001865.jpg, createdBy=c7881618185, createdName=qian0416, createdTime=Mon May 16 18:33:00 CST 2016, time=2016-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85979, encodeId=0d6f859e973, content=每一个东西都是有寿命, beContent=null, objectType=article, channel=null, level=null, likeNumber=183, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Mon May 16 13:39:00 CST 2016, time=2016-05-16, status=1, ipAttribution=)]
    2017-01-12 zxl736
  2. [GetPortalCommentsPageByObjectIdResponse(id=1633823, encodeId=2011163382348, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Thu Jan 12 04:11:00 CST 2017, time=2017-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486420, encodeId=f680148642040, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Wed May 18 02:11:00 CST 2016, time=2016-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86012, encodeId=c7978601254, content=每一个东西都是有寿命, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cache2.medsci.cn/upload/content/day_160326/201603262025001865.jpg, createdBy=c7881618185, createdName=qian0416, createdTime=Mon May 16 18:33:00 CST 2016, time=2016-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85979, encodeId=0d6f859e973, content=每一个东西都是有寿命, beContent=null, objectType=article, channel=null, level=null, likeNumber=183, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Mon May 16 13:39:00 CST 2016, time=2016-05-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1633823, encodeId=2011163382348, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Thu Jan 12 04:11:00 CST 2017, time=2017-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486420, encodeId=f680148642040, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Wed May 18 02:11:00 CST 2016, time=2016-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86012, encodeId=c7978601254, content=每一个东西都是有寿命, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cache2.medsci.cn/upload/content/day_160326/201603262025001865.jpg, createdBy=c7881618185, createdName=qian0416, createdTime=Mon May 16 18:33:00 CST 2016, time=2016-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85979, encodeId=0d6f859e973, content=每一个东西都是有寿命, beContent=null, objectType=article, channel=null, level=null, likeNumber=183, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Mon May 16 13:39:00 CST 2016, time=2016-05-16, status=1, ipAttribution=)]
    2016-05-16 qian0416

    每一个东西都是有寿命

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1633823, encodeId=2011163382348, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Thu Jan 12 04:11:00 CST 2017, time=2017-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486420, encodeId=f680148642040, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Wed May 18 02:11:00 CST 2016, time=2016-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86012, encodeId=c7978601254, content=每一个东西都是有寿命, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cache2.medsci.cn/upload/content/day_160326/201603262025001865.jpg, createdBy=c7881618185, createdName=qian0416, createdTime=Mon May 16 18:33:00 CST 2016, time=2016-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85979, encodeId=0d6f859e973, content=每一个东西都是有寿命, beContent=null, objectType=article, channel=null, level=null, likeNumber=183, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Mon May 16 13:39:00 CST 2016, time=2016-05-16, status=1, ipAttribution=)]
    2016-05-16 文医生

    每一个东西都是有寿命

    0

相关资讯

Lancet:PCI术后停止双抗治疗后心血管事件风险与停用原因有关

研究要点: 1.经皮冠状动脉介入(PCI)术后停用双联抗血小板治疗(DAPT)会增加不良事件风险。本次研究旨在分析PCI术后不同DAPT停用模式与心血管风险的相关性。 2.研究结果发现,PCI术后停止双联抗血小板治疗后心血管事件发生风险与停用具体原因有关。 3.随访两年中,74%的主要不良事件发生于患者维持DAPT治疗的期间。 经皮冠状动脉介入(

结合新指南谈房颤患者PCI术后的抗栓治疗策略

  刘宇扬教授        心房颤动(房颤)的患病率随年龄增加而升高,年龄≥80岁的人群中患病率超过8%。中国目前约有5百万房颤患者。预计2050年,随着人口老龄化,全球房颤患者总数将比现在至少增加2.5倍。作为两种常见的心血管疾病,房颤和冠心病有着某些共同的危险因素,如糖尿病和高血压。与此同时,冠心病中的某些临床情况,如心力衰竭(HF),亦

Baidu
map
Baidu
map
Baidu
map